Oncopeptides – First patients in Spain to be treated with Pepaxti
STOCKHOLM – May 27, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that the first Spanish hospital will begin treating patients with Pepaxti.
The first order of the drug from a Spanish hospital follows the availability of Pepaxti in the Spanish healthcare system (“Nomenclator”), making it possible for healthcare providers to in certain cases order the product before regional access has been negotiated.
“The reception of this innovation in the medical community is a testament to the unmet medical need that this drug fills,” says Sofia Heigis, CEO of Oncopeptides. “We look forward to more patients and professionals both in Spain and the rest of Europe benefitting from the clinical and quality of life results demonstrated by this treatment.”
In total, 16 Spanish hospitals and more than 100 patients have participated in the clinical trials that have led to the approval of the first drug in the peptide conjugate class for the treatment of relapsed, refractory multiple myeloma.
For more information, including questions and answers for investors, please visit Oncopeptides’ website.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68
About Oncopeptides
Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com
